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Abstract 
Liver function tests are of critical importance for the management of patients with severe or 
terminal liver disease. They are also used as prognostic tools for planning liver resections. In 
recent years many transport systems have been identified, that also transport substances 
employed in liver function tests. Such substances include endogenous bilirubin or 
exogenously administered indocyanine green, agents for magnetic resonance imaging, agents 
for single photon emission computed tomography or agents for breath tests. The increasing 
functional and molecular information on the respective transport systems should improve the 
management and as a result the outcome of patients scheduled for liver surgery or 
transplantation. To achieve the latter goal, clinical studies that assess individual patients liver 
function over the course of their disease with liver function testes are needed to firmly 
establish and validate recently introduced and novel liver function markers. 
1. Introduction 
Prognostic tools are of critical importance for the management of patients with severe chronic 
liver disease or fulminant liver failure. They are also needed for planning liver resections in 
patients with hepatic malignancies. For the first situation, liver function tests and scoring 
systems have been established. In the latter case, functional liver volumetry is currently an 
important part of the assessment of patients prior to surgery (Vauthey et al., 2010). The 
classical scoring system used in patients with severe liver disease is the Child-Turcotte-Pugh 
score, which takes into account encephalopathy, ascites, bilirubin, albumin, and prothrombin 
time (Durand and Valla, 2008). This score is increasingly being replaced by the MELD score, 
which is calculated from plasma bilirubin, the international normalized ratio (INR), and 
plasma creatinine (Cholongitas et al., 2006). In both scores, plasma bilirubin is a parameter 
that monitors, among others, transport capacity of hepatocytes and biotransformation, i.e., the 
detoxifying capacity of the liver. Hepatocyte-mediated detoxification involves four phases: 
phase 0 represents the uptake of substances into hepatocytes, phase I metabolism of 
substances, phase II, conjugation and phase III export of substances and/or metabolites from 
hepatocytes (Petzinger and Geyer, 2006; Vavricka et al., 2002). Hence, transport proteins are 
key molecular components of the hepatocellular detoxification system (phase 0 and phase III) 
and consequently of liver function tests. Liver function tests utilizing exogenous indicators 
such as indocyanine green (ICG), bromosulphophthalein (BSP), fluorescent bile salt 
derivatives, agents for magnetic resonance imaging (MRI), single photon emission computed 
tomography (SPECT), or breath tests have been developed to complement the use of 
endogenous indicators (de Graaf et al., 2010a; Milkiewicz et al., 2000; Millet et al., 2011; 
Sakka, 2007). Preoperative dynamic liver function tests are part of the routine assessment of 
patients scheduled for liver resection in many centers (Breitenstein et al., 2009). Therefore, 
elucidation of the molecular mechanisms and especially the transport systems involved in 
dynamic liver function tests is highly warranted. 
 2. Transport systems in liver function tests 
 
2.1. Bilirubin 
Rat Oatp1a4 and human OATP1B1 and OATP1B3 (table 1) transport unconjugated or 
conjugated bilirubin (Briz et al., 2003; Cui et al., 2001b; Konig et al., 2000; Reichel et al., 
1999). Corroboratively, recent pharmacogenetic studies have linked polymorphisms in the 
SLCO1B1 and SLCO1B3 genes with unconjugated and conjugated plasma bilirubin levels 
(Johnson et al., 2009; Sanna et al., 2009; Zhang et al., 2007). A role of Oatps in hepatocellular 
bilirubin uptake is further supported by experiments with mice with deleted Slco1a and 
Slco1b genes. These animals display a greater than 40-fold increase in total plasma bilirubin, 
the major part of which is conjugated bilirubin, which is not detectable in the parent strain 
(van de Steeg et al., 2010). Unconjugated bilirubin is increased approximately 2.5-fold. While 
the cause of the conjugated bilirubin elevation has not been determined, the increase in 
unconjugated bilirubin supports a role of Oatps in hepatocellular uptake of bilirubin. Mild 
elevation of mainly conjugated bilirubin is also observed in mice with inactivated Slco1b2 
(Zaher et al., 2008), which was recently confirmed (Csanaky et al., 2011). Taken together, 
these human and animal data strongly support a physiological involvement of hepatocellular 
OATPs in the hepatic uptake of unconjugated and conjugated bilirubin. 
 
2.2. Bromosulphophthalein 
The first Oatp was isolated by expression cloning with BSP as substrate (Jacquemin et al., 
1994). In the human liver, the three OATPs (table 1) are excellent BSP transporters 
(Hagenbuch and Meier, 2004; Kullak-Ublick et al., 2001). After uptake into hepatocytes, BSP 
is conjugated to glutathione and excreted into bile (Combes and Stakelum, 1960) by Mrp2 in 
rats (Takikawa et al., 1991). Unconjugated BSP is also a substrate for MRP2 (Cui et al., 
2001a) (table 1). Hence, BSP clearance monitors both, hepatocellular transport and 
metabolism. Today, BSP clearance is rarely measured in patients, as it may be associated with 
severe systemic reactions (Sakka, 2007). 
 
2.3. Indocyanine green 
Oatp1a1 as well as OATP1A2, the first cloned human OATP, are strongly inhibited by ICG 
(Bossuyt et al., 1996; Kullak-Ublick et al., 1995) (table 1). Recently, OATP1B3 and the 
human sodium-taurocholate cotransporting polypeptide (NTCP, SLC10A1) have been 
demonstrated to transport ICG (table 1), while OATP1B1 (IC50= 3.2 µM) and OATP2B1 
(IC50= 0.08 µM) are strongly inhibited by ICG but do not transport ICG (de Graaf et al., 
2011). ICG is not subject to hepatic metabolism (Wheeler et al., 1958). Eisai rats lacking 
functional Mrp2 reveal that biliary ICG excretion is mediated by Mrp2 (Sathirakul et al., 
1993) (table 1). Delayed residual ICG excretion in these rats indicates an additional 
transcellular pathway for ICG. This view is supported by the observations that the 
microtubule disrupting agent colchicine partially inhibits biliary ICG excretion (Mori et al., 
1987). 
 
2.4. Fluorescently labeled bile salts 
Reduced clearance of cholyl-glycine is a known phenomenon in patients with liver disease 
(LaRusso et al., 1975) and the clearances of cholyl-taurine and ICG correlate well 
(Paumgartner et al., 1979). Fluorescently labeled bile salts have been suggested as liver 
function indicators on the basis of a pilot study that demonstrated reduced clearance of cholyl-
lysyl-fluorescein (CLF) in patients with liver cirrhosis (Milkiewicz et al., 2000). CLF is not a 
substrate of the major bile salt transporters NTCP and bile salt export pump (BSEP), but of 
OATP1B3, weakly of OATP1B1, and of the efflux transporters MRP2 and MRP3 (de Waart 
et al., 2010) (table 1). Fluorescent chenodeoxycholic acid 7-nitrobenz-2-oxa-1,3-diazole is 
transported by OATP1B1 and OATP1B3 (Yamaguchi et al., 2006). 
 
2.5. Erythromycin 
The erythromycin breath test assesses the biotransformation function of the liver. 
Erythromycin inhibits OATP1B1 and OATP1B3 (Seithel et al., 2007), is transported by 
OATP1B1 (Franke et al., 2008) and is a substrate for MRP2 (Franke et al., 2011) (table 1). 
MRP2-mediated transport affects the metabolism of erythromycin in humans (Franke et al., 
2011). Consequently, the interplay between transport and metabolism is of relevance for 
determining liver function by erythromycin. 
 
2.6. MRI and scintigraphic agents 
The MRI agent gadoxetate (gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid, 
Gd-EOB-DTPA) or gadobenate (gadolinium benzyloxyproprionictetraacteate, Gd-BOPTA) 
are used to evaluate focal liver lesions by T1-weighted MRI imaging and more recently to 
evaluate liver function. Gadoxetate is excreted unaltered into rat bile (Weinmann et al., 1991) 
and its secretion into bile is almost completely blocked, when the animals are pretreated with 
BSP (de Haen et al., 1995). Rat Oat1a1, but not Oat1a4 or OATP1A2 (table 1), were found to 
transport gadoxetate (van Montfoort et al., 1999). Biliary gadoxetate excretion is massively 
reduced in TR- rats with no functional Mrp2 (de Haen et al., 1996). The structurally closely 
related Gd-BOPTA is taken up into rat hepatocytes by Oatp1a1, Oatp1a4, and Oatp1b2 and 
excreted into bile by Mrp2 (Planchamp et al., 2007). Recently, the scintigraphic agent 99mTc-
mebrofenin was introduced for assessing liver function noninvasively (de Graaf et al., 2010a) 
and for predicting the function of the future remnant liver after liver resection (de Graaf et al., 
2010b). Subsequent studies identified OATP1B1 and OATP1B3 as 99mTc-mebrofenin uptake 
transporters (de Graaf et al., 2011; Ghibellini et al., 2008). Biliary excretion of 99mTc-
mebrofenin is mediated by MRP2 and basolateral efflux by MRP3 (Ghibellini et al., 2008) 
(table 1). 
 
3. Impact of transport processes on liver function tests 
 
3.1. Effect of dose of the indicator 
As transport systems exhibit saturation, the disappearance of the indicator from the blood may 
- depending on its dose - follow simple or complex kinetics. Thus, the plasma concentration 
of the indicator following administration may affect its kinetics. This phenomenon has been 
worked out in detail for ICG. This prototypic indicator is almost exclusively eliminated by the 
liver and can be used for monitoring hepatocellular transport function as it is not metabolized. 
At low doses, ICG behaves as a high extraction drug. Consequently its plasma clearance is 
mainly determined by liver blood flow and it is not a sensitive parameter of the liver excretory 
functional capacity. At high doses, ICG displays saturation of the clearance and mainly 
reflects the transport capacity of the liver (Paumgartner, 1975). 
 
3.2. Importance of transport mechanism 
The type of transport mechanism will affect the clearance of the liver function indicators. For 
example, NTCP is a secondary active, electrogenic transporter that mediates substrate uptake 
by utilizing the electrochemical sodium gradient across the basolateral plasma membrane of 
hepatocytes (Stieger, 2011). This driving force is maintained by the (Na+K)-ATPase, which 
requires a continuous supply of ATP. 
 
The transport mechanism(s) of OATPs is not fully understood (Hagenbuch and Gui, 2008). 
They are believed to act as organic anion exchangers with bicarbonate (Satlin et al., 1997) 
and/or reduced or oxidized glutathione (Briz et al., 2006; Li et al., 1998; Li et al., 2000) acting 
as counterions. Recently, evidence was presented that the activity of practically all OATPs is 
stimulated by a low extracellular pH and that many OATPs act as anion-exchangers with 
bicarbonate as counter ion (Leuthold et al., 2009). Hence, while anion exchange as basic 
transport mechanism of OATPs seems well established, clearly more work is needed to obtain 
detailed insights. 
 
The transport mechanism will influence the capacity of OATPs to take up liver function 
indicators into hepatocytes. If OATPs can work against a concentration gradient, the 
consequence will be an intracellular concentration exceeding the plasma concentration. ICG 
has been found at approximately 10-fold higher concentration in rat liver than in plasma 
(Horak et al., 1973). Similarly, glibenclamide is 50 times higher concentrated in rat livers than 
in plasma (Kellner et al., 1969). Glibenclamide inhibits OATP1B1 and OATP1B3, making it 
a likely substrate for OATPs (Bednarczyk, 2010). Hepatocellular concentrations of liver 
function indicators are not only determined by uptake into hepatocytes but also by the relative 
rate of export, as recently demonstrated for Gd-BOPTA (Millet et al., 2011). Perfusing wild 
type and TR- rat livers with increasing concentrations of Gd-BOPTA showed unaltered Km of 
hepatic uptake and only a 25 % reduction in Vmax in TR- compared to wild type rats despite a 
lack of biliary secretion in the mutant rats. Hence, the interplay of uptake and export is 
intricate. Complex interplay between uptake and efflux was also demonstrated for 
fexofenadine and napsagatran (Poirier et al., 2009). 
 
3.3. Interindividual variability of transporter expression 
Transporter expression displays a considerable interindividual variability (Ohtsuki et al., 
2011). In healthy liver tissue from 110 individuals, protein expression of the four canalicular 
transporters BSEP, MDR3, MRP2 and MDR1 displayed a considerable, up to 33-fold, 
interindividual variability (Meier et al., 2006). Such interindividual differences in transporter 
expression levels are expected to affect the clearance of liver function indicators. 
 
3.4. Transporter expression in liver disease 
The expression of hepatocellular transporters may be altered divergently in liver disease. For 
instance, progressive familial intrahepatic cholestasis leads to downregulation of NTCP, 
OATP1B1, OATP1B3, and MRP2, while MRP4 is upregulated (Keitel et al., 2005). Patients 
with inflammatory cholestasis, primary biliary cirrhosis or chronic hepatitis C show a 
reduction of protein expression for NTCP and OATP1B1 (Zollner et al., 2003; Zollner et al., 
2001), while expression of MRP3, MRP2, MDR1, and MDR3 is upregulated and BSEP is not 
affected (Zollner et al., 2003). Hence, clearance prediction of liver function indicators is 
difficult in disease situations. The alteration of transporter expression is not always evenly 
distributed throughout the liver. For instance, some hepatocellular carcinomas display poor 
MRI enhancement with gadoxetic acid. The enhancement correlates positively with 
OATP1B1 and OATP1B3 and negatively with MRP2 expression (Tsuboyama et al., 2010). 
 
3.5. Interaction of drugs with transport systems 
Drugs that inhibit transporters of liver function indicators may influence liver function tests. 
For example, uptake of ICG is inhibited by rifamycin (Paumgartner, 1975), which is a potent 
liver OATP inhibitor (Fattinger et al., 2000; Vavricka et al., 2002). In contrast, co-
administration of erythromycin and gadoxetic acid was recently found to have no effect on 
liver imaging (Huppertz et al., 2011). 
 
4. Perspective 
Taken altogether, it is now well established that transport systems are key elements in most, if 
not all currently used liver function tests. Consequently, read outs from liver function tests 
represent a complex interplay between uptake of the indicator, its potential metabolism, and 
its bidirectional export from hepatocytes. This complexity of the monitored physiological 
and/or pathophysiological processes makes it highly likely that one single test of liver 
function is of limited predictive value. The challenge will now be to delineate in prospective 
studies a set of liver function tests to be applied in clinics for predictive purposes. 
 
One potential patient collective to be addressed is for example patients on the waiting list for 
organ transplantation, who are currently prioritized by means of the MELD score and by 
changes in the MELD score. However, certain diseases underlying liver failure necessitate 
exceptions from the MELD score (Massie et al., 2011). In such cases, novel markers of global 
liver function are needed and should be compared with the MELD score in individual 
patients. An important criterion will be that such a novel marker performs better than the ICG 
clearance test, which is known to suffer from inaccuracy and limited reproducibility 
(Schneider, 2004). In regard to the MELD score, it should also be borne in mind that patients 
with cirrhosis potentially present with factors that lead to falsely low plasma creatinine 
values, which will overestimate the true glomerular filtration rate (Sherman et al., 2003). This 
will lower their MELD score and hence potentially lead to a too low priority rating on waiting 
lists. Again, novel global liver function tests may be a solution here. 
 
In the case of planned liver resections, information on the liver function of individual 
segments is needed to successfully improve the outcome of this procedure (de Graaf et al., 
2010a; Hoekstra et al.). Noninvasive methods such as scintigraphy or MRI are already under 
clinical investigation and have demonstrated to predict the remaining functional liver mass in 
patients scheduled for resection (de Graaf et al., 2010c). Future studies should be designed 
such that they yield a clear definition and grading of posthepatectomy liver failure, which is 
currently not classified by a generally accepted scoring system (Rahbari et al., 2011). In all 
instances, future clinical studies should certainly involve longitudinal studies in individual 
patients, e.g., those listed for transplantation to overcome inherent limitations such as 
interindividual differences in transporter expression (Meier et al., 2006; Ohtsuki et al., 2011). 
Longitudinal studies will be particularly attractive with tests that can be monitored 
transcutaneously in a given patient, e.g., ICG clearance (Sakka, 2007) or 99mTc-mebrofenin 
(de Graaf et al., 2010b). 
 
Given the current knowledge on the role of transport proteins in the molecular mechanisms 
underlying liver function tests, more information on the function and expression of these 
transporters is needed. In this respect, quantitative proteomics has become a highly attractive 
tool for the determination of transporter expression levels in individual patients (Ohtsuki et 
al., 2011). A possible scenario could involve the intraoperative determination of the clearance 
of a liver function marker with simultaneous proteomic determination of transporters in the 
resected liver tissue. A proof-of-principle for such an approach has now been established for 
transporter expression in the blood-brain barrier in an animal model (Ito et al., 2011). Finally, 
the successful establishment of tests to reliably predict the functional capacity of the future 
remnant liver will hopefully improve the management and, as a result, the outcome of patients 
undergoing liver resection. 
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Extensive information on the known functional variants of the transporters can be found in 
(Stieger and Meier, 2011) except for 1(Kalliokoski and Niemi, 2009) and 2(Stieger, 2011). 
BSP: bromosulphophthalein, CLF: cholyl-lysyl-fluorescein, ICG: indocyanine green 
